Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Allergan's UK Generics Business Up For Sale Under EC Merger Condition

This article was originally published in Scrip

Executive Summary

The European Commission has approved the proposed $40.5bn acquisition of the generics business of Allergan (the company formerly known as Actavis) by Teva, subject to a number of significant conditions, including the divestment of the majority of Allergan Generics' business in the UK and Ireland.

Advertisement

Related Content

Intas' MD On Acquiring Best-Performing Assets And Brexit
Intas Builds Europe Scale With £603m Teva Deal
M&A Trends: The Growing Indian Appetite
FTC Review Ongoing As Teva/Allergan Await Final Approval
'No Meaningful Change' In Pricing Environment, Teva Says

Topics

Advertisement
UsernamePublicRestriction

Register

SC064750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel